The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that BEYFORTUS provides protection for babies ...

AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory ...

A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

Sanofi (NASDAQ:SNY) said that a recent U.S. study found that its Beyfortus (nirsevimab) injection successfully met its main goals, showing that it helps protect infants from respiratory syncytial ...

Find out whether you should get the RSV vaccine, known as Abrysvo, during pregnancy and when it's recommended.

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

Parental trust in clinicians drove RSV vaccine uptake, while confusion and limited access to reliable information hindered ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

The team identified more than 7,200 babies eligible to have received nirsevimab during its inaugural 2023-24 RSV season. But ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology ...